Plain-English translation of NCT07231445 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called , given together with immune checkpoint inhibitor medications (which help your body fight cancer), to treat extensive-stage small cell lung cancer. Researchers want to see if this combination is safe and whether it works better than standard treatment alone. You would receive the medication as part of a carefully monitored study involving about 100 participants.
Small cell lung cancer is aggressive and difficult to treat, especially once it has spread widely in the body. This trial exists to see whether this new combination approach can improve outcomes for patients who are starting treatment for the first time.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly to receive the medication intravenously (through an IV) and to have your health monitored with blood tests and scans. The exact schedule and duration would be explained during your screening visit. Throughout the study, the research team will carefully track how you respond to the treatment and watch for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China